• In late July 2026, Hims & Hers Health responded to a lawsuit from the Federal Trade Commission, Utah, and Los Angeles County alleging deceptive subscription practices and improper sharing of sensitive patient data with advertising platforms, firmly rejecting the claims and vowing to defend its telehealth business model and privacy practices.
• The company argues the case ignores industry norms and its consent-based data policies, framing the action as headline-driven rather than consumer-protection-driven, which raises fresh questions for investors about regulatory risk, customer trust, and the resilience of its direct-to-consumer platform.
• We’ll now examine how this new FTC legal challenge to Hims & Hers’ subscription and data practices may reshape its broader investment narrative.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers, you have to believe in its direct to consumer telehealth platform, recurring subscriptions, and expanding treatment categories. The FTC lawsuit squarely targets subscription and data practices that underpin that model, so it meaningfully increases near term regulatory and reputational risk, even as weight loss and daily programs remain the key growth catalyst many are watching.

The company’s March 2026 collaboration with Novo Nordisk to offer Wegovy through its platform sits right at the intersection of those catalysts and risks. It links Hims & Hers’ high demand weight loss offering to a major drug manufacturer while the FTC case scrutinizes how subscriptions are marketed and how sensitive health data is handled, so investors will likely watch how both developments evolve together.

Yet behind the headline growth story, rising regulatory scrutiny of data, subscriptions, and telehealth prescriptions could quietly reshape the risk profile investors need to understand...

Hims & Hers Health's narrative projects $5.6 billion revenue and $211.5 million earnings by 2029. This requires 33.0% yearly revenue growth and a $224.7 million earnings increase from -$13.2 million today.

Uncover how Hims & Hers Health's forecasts yield a $28.42 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were penciling in about US$5.9 billion of revenue and US$240.7 million of earnings by 2029, but the FTC’s focus on telehealth data and subscriptions could challenge those assumptions, so you should weigh their upbeat view on margins against the real possibility that higher compliance costs or tighter rules change the story.

Explore 25 other fair value estimates on Hims & Hers Health - why the stock might be worth 16% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.